BK1326 Traditional Chinese Medicine
- 964.857
- -0.939-0.10%
Tong Ren Tang Chinese Medicine (03613.HK): “Angelica Blood Supplement Granules [Tong Ren Tang]” approved for sale in Hong Kong
Gelonghui, April 30, 丨 Tong Ren Tang Chinese Medicine (03613.HK) announced that the company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, permitting the sale of “Angelica Supplementation Granules [Tong Ren Tang]” in Hong Kong. The relevant information notice is as follows: Drug Name: Angelica Blood Supplementation Granules [Tong Ren Tang]; Registered Holder and Address: Beijing Tong Ren Tang Sinopharm Co., Ltd., No. 3, Da Jing Street, Tai Po Industrial Estate, New Territories, Hong Kong; registration number: HKC-18604; certificate validity period: until April 25, 2029.” The main function of “Angelica Blood Supplementation Granules [Tong Ren Tang]”
現代中藥集團：2023年報
Tong Ren Tang Chinese Medicine (03613): Issued a certificate of registration for proprietary Chinese medicines
According to Zhitong Finance App, Tong Ren Tang Sinopharm (03613) issued an announcement. The company recently received the “Certificate of Registration for Proprietary Chinese Medicines” issued by the Hong Kong Traditional Chinese Medicine Administration, which allows the sale of “Angelica Blood Supplementation Granules [Tong Ren Tang]” in Hong Kong.
Express News | Tong Ren Tang: Holding Sun Company obtained the Hong Kong Proprietary Chinese Medicine Registration Certificate for Angelica Blood Supplements
Tong Ren Tang's Q1 Profit Jumps 10%, Revenue Rises 2%
Beijing Tong Ren Tang Group's (SHA:600085) attributable net profit edged up 10% year over year in the first quarter to 575.9 million yuan from 523.4 million yuan a year earlier, the company said in a
Express News | Baiyun Mountain: Wang Laoji collaborates with KFC
康臣葯業：股東周年大會通告
康臣葯業：2023 年度報告
綠葉製藥：年報 2023
培力農本方：2023年度報告
Express News | Tong Ren Tang: Net profit from mother for the first quarter was 576 million yuan, up 10.04% year on year
April 26 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.74,141 million
According to HKEx's April 29 disclosure documents, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 26, involving an amount of HK$6,1714,400. The repurchase price per share ranged from HK$103.3 to HK$102.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) was 6.314 million shares, accounting for 0.33% of the number of shares issued when the ordinary resolution was passed. ② $too
China Resources Pharmaceutical (03320.HK): Jiangzhong Pharmaceutical's net profit of 267 million yuan in the first quarter increased 9.99% year-on-year
Gelonghui, April 29丨China Resources Pharmaceutical (03320.HK) announced that Jiangzhong Pharmaceutical (600750.SH) achieved operating income of 1,227 billion yuan in the first quarter of 2024, down 8.74% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) was 267 million yuan, up 9.99% year on year; net profit attributable to shareholders of listed companies (Jiangzhong Pharmaceutical) after deducting non-recurring profit and loss was 264 million yuan, up 16.64% year on year.
華潤醫藥：公告江中藥業截至2024年3月31日止三個月的未經審核財務業績
Featured announcements | The total amount of AIA share repurchase plans increased to US$12 billion; Sinopec's net profit for the first quarter decreased 8.9% year-on-year
China Shenhua's net profit for the first quarter was 15.884 billion yuan, a year-on-year decrease of 14.7%; China Life Insurance's net profit for the first quarter was 20.644 billion yuan, a decrease of 9.3% year-on-year.
Gushengtang (2273.HK): Maintaining rapid business growth in 1Q24
Goseido updated its 1Q24 business data. The number of patients treated in 1Q24 was about 1.07 million, an increase of about 42.1% over the previous year. Among these, newly established stores were 1Q from April 1, 23 to March 31, 24
Express News | China Stem Cell Group signs contract with China Resources Pharmaceutical Commercial Group to complement each other's strengths and promote transformation of results
Insider Buying: Fusen Pharmaceutical Executive Chairman Bought CN¥908k Of Shares
Investors who take an interest in Fusen Pharmaceutical Company Limited (HKG:1652) should definitely note that the Executive Chairman, Changcheng Cao, recently paid HK$0.87 per share to buy HK$908k wor
Express News | Lingnan Holdings: Guangzhou Travel Yuejing Company plans to acquire 100% of Baiyunshan Travel Development's shares for 6.151,800 yuan
Gushengtang Logs 42% Boost in Q1 Customer Visits
Gushengtang Holdings (HKG:2273) recorded around 1.1 million customer visits during the three months ended March 31, up 42.1% from the year-ago figure of 756,000 visits, a Thursday filing on the Hong K